Connect with us

Surmontil (trimipramine)


Trimipramine (or SURMONTIL®) is mainly prescribed to treat major depressive disorderacute anxiety, and insomnia.

Status: ACTIVE

Class: Tricyclic (TCA)

FDA Approval: 1979

Dosage Forms: 25 mg, 50 mg, 100 mg

Biological Half-life: 23-24 hours

Side Effects: Dizziness, sleepiness, dry mouth, blurred vision, constipation, diarrhea, tingly sensation, weakness, lack of coordination, appetite changes, low libido, increased suicide risk

Routes of Administration: Oral, IM, IV

Pregnancy Category: C (US)

  www.fda.gov

Like Us

Advertisement
Advertisement